Orchard Therapeutics plc Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $225 million initial public offering by Orchard Therapeutics…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Davis Polk Advises Tokyu Fudosan Holdings Corporation on Its ¥55.3 Billion Follow-On Equity Offering
Davis Polk advised Tokyu Fudosan Holdings Corporation in connection with a follow-on offering of 80,436,000 shares of common stock. In addition, the underwriters have over-allotment options…
StoneCo $1.4 billion IPO and concurrent private placement
Davis Polk advised StoneCo Ltd. on its $1.4 billion initial public offering of 58,333,333 shares of Class A common stock, which includes the full exercise of the underwriters’ option to…
Davis Polk Advises Árima Real Estate SOCIMI, S.A. on Its €100 Million Initial Offering
Davis Polk advised Árima Real Estate SOCIMI, S.A. on the Rule 144A/Regulation S initial offering by Árima of 10,000,000 of Árima’s ordinary shares, raising gross proceeds of €100 million…
Davis Polk Advises Ferguson plc on Its $750 Million Senior Notes Offering
Davis Polk advised Ferguson plc in connection with its debut Rule 144A/Regulation S offering of $750 million aggregate principal amount of 4.500% notes due 2028 by Ferguson Finance plc. The…
SolarWinds $375 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 25,000,000 shares of common stock of SolarWinds Corporation. The…
Studio City International Holdings Limited $359.4 Million Initial Public Offering
Davis Polk advised the representatives of the underwriters on the SEC-registered initial public offering by Studio City International Holdings Limited of 28,750,000 American Depositary…
Davis Polk Advises Laboratorios Farmacéuticos Rovi, S.A. on Its €80 Million Follow-On Offering
Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of its ordinary shares to raise gross proceeds of approximately €80…
Davis Polk Advises Sumitomo Mitsui Banking Corporation on Its $1 Billion Notes Offering
Davis Polk advised Sumitomo Mitsui Banking Corporation in connection with a global medium-term note program update and a benchmark takedown, which consisted of $1 billion aggregate…
Davis Polk Advises Sumitomo Mitsui Financial Group, Inc. on Its $2.5 Billion SEC-Registered Notes Offering
Davis Polk advised Sumitomo Mitsui Financial Group, Inc. on its SEC-registered takedown offering of senior TLAC notes, which consisted of $1 billion aggregate principal amount of 3.936%…